108 related articles for article (PubMed ID: 1748213)
21. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.
Babudri N; Pani B; Tamaro M; Monti-Bragadin C; Zunino F
Br J Cancer; 1984 Jul; 50(1):91-6. PubMed ID: 6378238
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
Ohkawa K; Hatano T; Tsukada Y; Matsuda M
Br J Cancer; 1993 Feb; 67(2):274-8. PubMed ID: 8431358
[TBL] [Abstract][Full Text] [Related]
23. Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitro.
Dessypris EN; Brenner DE; Hande KR
Cancer Treat Rep; 1986 Apr; 70(4):487-90. PubMed ID: 3698042
[TBL] [Abstract][Full Text] [Related]
24. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
[TBL] [Abstract][Full Text] [Related]
25. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Takahashi N; Li WW; Banerjee D; Scotto KW; Bertino JR
Clin Cancer Res; 2001 Oct; 7(10):3251-7. PubMed ID: 11595721
[TBL] [Abstract][Full Text] [Related]
26. The effect of ultrasound on the cytotoxicity of adriamycin.
Loverock P; ter Haar G; Ormerod MG; Imrie PR
Br J Radiol; 1990 Jul; 63(751):542-6. PubMed ID: 2390688
[TBL] [Abstract][Full Text] [Related]
27. Comparative pharmacokinetics of tetrahydropyranyl-doxorubicin and doxorubicin in rat isolated lung.
Dumas M; Dubuet A; D'Athis P; Camus P; Escousse A
J Pharm Pharmacol; 1992 Jan; 44(1):58-60. PubMed ID: 1350631
[TBL] [Abstract][Full Text] [Related]
28. Correlation between growth inhibition and intranuclear doxorubicin and 4'-deoxy-4'-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry.
Gigli M; Rasoanaivo TW; Millot JM; Jeannesson P; Rizzo V; Jardillier JC; Arcamone F; Manfait M
Cancer Res; 1989 Feb; 49(3):560-4. PubMed ID: 2910478
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the in vitro effect of adriblastina on induction of SCEs in V79 cells and human peripheral blood lymphocytes.
Szabová E
Neoplasma; 1996; 43(6):407-9. PubMed ID: 8996566
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
31. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.
Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P
Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080
[TBL] [Abstract][Full Text] [Related]
32. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats.
Fadillioglu E; Oztas E; Erdogan H; Yagmurca M; Sogut S; Ucar M; Irmak MK
J Appl Toxicol; 2004; 24(1):47-52. PubMed ID: 14745846
[TBL] [Abstract][Full Text] [Related]
33. The cytotoxicity of mitomycin C and adriamycin in genetically engineered V79 cell lines and freshly isolated rat hepatocytes.
Goeptar AR; te Koppele JM; Glatt HR; Groot EJ; Seidel A; Barrenscheen M; Wölfel C; Doehmer J; Vermeulen NP
Chem Biol Interact; 1995 Jul; 97(2):149-68. PubMed ID: 7606813
[TBL] [Abstract][Full Text] [Related]
34. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
Hatano T; Ohkawa K; Matsuda M
Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic and genotoxic properties of tert.-butyl-p-quinone (TBQ) in an in vitro assay system with Chinese hamster V79 cells and in strain D7 of Saccharomyces cerevisiae.
Rogers CG; Boyes BG; Matula TI; Neville G; Stapley R
Mutat Res; 1993 Mar; 299(1):9-18. PubMed ID: 7679195
[TBL] [Abstract][Full Text] [Related]
37. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
[TBL] [Abstract][Full Text] [Related]
38. Macrophages loaded with doxorubicin by ATP-mediated permeabilization: potential carriers for antitumor therapy.
Munerati M; Cortesi R; Ferrari D; Di Virgilio F; Nastruzzi C
Biochim Biophys Acta; 1994 Nov; 1224(2):269-76. PubMed ID: 7981242
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of mutagenicity and antimutagenicity of cashew stem bark methanolic extract in vitro.
Barcelos GR; Shimabukuro F; Mori MP; Maciel MA; Cólus IM
J Ethnopharmacol; 2007 Nov; 114(2):268-73. PubMed ID: 17889467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
